Opdam MAA - Search Results

1

Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population.

Popa CD, Opdam MAA, den Broeder N, van Ballegooijen H, Mulder K, van de Wiel KM, van Herwaarden N, Wientjes MHM, den Broeder AA. Popa CD, et al. Among authors: opdam maa. Rheumatology (Oxford). 2024 Aug 1;63(8):2142-2146. doi: 10.1093/rheumatology/kead531. Rheumatology (Oxford). 2024. PMID: 37796830

2

Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells.

Opdam MAA, de Leijer JH, den Broeder N, Thurlings RM, van der Weele W, Nurmohamed MT, Kok MR, van Bon L, Ten Cate DF, Verhoef LM, den Broeder AA. Opdam MAA, et al. Rheumatology (Oxford). 2022 Dec 23;62(1):330-334. doi: 10.1093/rheumatology/keac318. Rheumatology (Oxford). 2022. PMID: 35686851

3

Hypogammaglobulinemia in rheumatoid arthritis patients on rituximab: prevalence and risk factors.

Opdam MAA, Campisi LM, de Leijer JH, Ten Cate D, den Broeder AA. Opdam MAA, et al. Rheumatology (Oxford). 2024 Jan 4;63(1):e1-e2. doi: 10.1093/rheumatology/kead326. Rheumatology (Oxford). 2024. PMID: 37410082 No abstract available.

4

Exploring the perspective of patients with immune-mediated inflammatory diseases and care providers on the use of immunomodulatory drugs in infections: an interview study.

Opdam MAA, Vriezekolk JE, Broen J, den Broeder AA, Verhoef LM. Opdam MAA, et al. Rheumatol Adv Pract. 2023 Jan 11;7(1):rkad003. doi: 10.1093/rap/rkad003. eCollection 2023. Rheumatol Adv Pract. 2023. PMID: 36685994 Free PMC article.

5

Identification of Risk Factors for COVID-19 Hospitalization in Patients With Anti-Rheumatic Drugs: Results From a Multicenter Nested Case Control Study.

Opdam MAA, Benoy S, Verhoef LM, Van Bijnen S, Lamers-Karnebeek F, Traksel RAM, Vos P, den Broeder AA, Broen J. Opdam MAA, et al. Clin Pharmacol Ther. 2022 May;111(5):1061-1065. doi: 10.1002/cpt.2551. Epub 2022 Feb 23. Clin Pharmacol Ther. 2022. PMID: 35143039 Free PMC article.

6

Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.

Opdam MAA, Broeder ND, van den Bemt BJF, Mulder K, van de Wiel KM, van Ballegooijen H, van Crevel R, den Broeder AA. Opdam MAA, et al. Clin Rheumatol. 2024 Jun;43(6):2133-2138. doi: 10.1007/s10067-024-06980-x. Epub 2024 May 4. Clin Rheumatol. 2024. PMID: 38703283

7

Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.

Veeken LD, Opdam MAA, Verhoef LM, Popa C, van Crevel R, den Broeder AA. Veeken LD, et al. Among authors: opdam maa. Rheumatology (Oxford). 2024 May 2;63(5):1246-1250. doi: 10.1093/rheumatology/kead328. Rheumatology (Oxford). 2024. PMID: 37410085

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters